Free Trial

Genmab A/S (GMAB) Insider Trading & Ownership

Genmab A/S logo
$20.31 +0.22 (+1.10%)
(As of 12/20/2024 05:16 PM ET)

There is no recent insider trading on record for Genmab A/S, but the stock has been recently traded by U.S. Congress members, who may have more information about the industry than the general public.

Get GMAB Insider Trade Alerts

Want to know when executives and insiders are buying or selling Genmab A/S stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

Genmab A/S Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellAverage Share PriceTotal Transaction
7/19/2024Josh GottheimerU.S. Congress Member (D-NJ)Buy$27.75$1,001 - $15,000
6/18/2024Josh GottheimerU.S. Congress Member (D-NJ)Sell$25.80$1,001 - $15,000
10/16/2023Josh GottheimerU.S. Congress Member (D-NJ)Buy$32.55$1,001 - $15,000
9/15/2023Josh GottheimerU.S. Congress Member (D-NJ)Sell$37.98$1,001 - $15,000
7/20/2023Josh GottheimerU.S. Congress Member (D-NJ)Buy$41.45$1,001 - $15,000
7/19/2023Josh GottheimerU.S. Congress Member (D-NJ)Buy$40.90$1,001 - $15,000
7/10/2023Daniel S. GoldmanU.S. Congress Member (D-NY)Sell$37.86$50,001 - $100,000
3/31/2023Daniel S. GoldmanU.S. Congress Member (D-NY)Sell$37.76$1,001 - $15,000
(Data available from 1/1/2013 forward)

GMAB Insider Trading Activity - Frequently Asked Questions

1.54% of Genmab A/S stock is owned by insiders. Learn more on GMAB's insider holdings.

Josh Gottheimer (D-NJ) has bought shares of Genmab A/S in the last year totaling $8,000. Josh Gottheimer (D-NJ) has sold shares totaling $8,000.

Genmab A/S Key Executives

  • Dr. Jan G.J. van de Winkel Ph.D. (Age 63)
    Co-Founder, President & CEO
    Compensation: $2.9M
  • Mr. Anthony Pagano (Age 46)
    Executive VP & CFO
    Compensation: $1.03M
  • Mr. Anthony Mancini (Age 53)
    Executive VP & COO
    Compensation: $1.14M
  • Ms. Birgitte Stephensen M.Sc. (Age 63)
    Executive VP & Chief Legal Officer
    Compensation: $637.57k
  • Mr. Christopher Cozic (Age 45)
    Executive VP & Chief People Officer
    Compensation: $782.47k
  • Dr. Martine J. van Vugt Ph.D. (Age 53)
    Executive VP & Chief Strategy Officer
    Compensation: $695.53k
  • Mr. Martin Schultz (Age 48)
    Senior Director of Clinical Operations & Non-Independent Director
    Compensation: $115.92k
  • Dr. Judith V. Klimovsky M.D. (Age 66)
    Executive VP & Chief Development Officer
    Compensation: $1.17M
  • Dr. Tahamtan Ahmadi (Age 51)
    Executive VP, Chief Medical Officer & Head of Experimental Medicines
    Compensation: $1.12M
  • Dr. Mijke Zachariasse Ph.D. (Age 50)
    Senior Director, Head of Antibody Research Materials & Non-Independent Director
    Compensation: $159.39k


This page (NASDAQ:GMAB) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners